|
Volumn 42, Issue 6, 2001, Pages 1379-1383
|
Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia
a a a a a |
Author keywords
CAMPATH 1H; Chemotherapy; Phenotypic switch; T cell prolymphocytic leukaemia
|
Indexed keywords
ALEMTUZUMAB;
BLEOMYCIN;
CD19 ANTIGEN;
CD2 ANTIGEN;
CD3 ANTIGEN;
CD4 ANTIGEN;
CD52 ANTIGEN;
CD7 ANTIGEN;
CD8 ANTIGEN;
CLADRIBINE;
CYCLOPHOSPHAMIDE;
CYCLOSPORIN A;
CYTARABINE;
DANAZOL;
DOXORUBICIN;
ERYTHROPOIETIN;
ETOPOSIDE;
GANCICLOVIR;
GRANULOCYTE COLONY STIMULATING FACTOR;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
METHOTREXATE;
MITOMYCIN;
PENTOSTATIN;
PREDNISONE;
T LYMPHOCYTE RECEPTOR ALPHA CHAIN;
T LYMPHOCYTE RECEPTOR BETA CHAIN;
VINCRISTINE SULFATE;
ADULT;
ANTIGEN EXPRESSION;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER RECURRENCE;
CANCER RESISTANCE;
CASE REPORT;
CHROMOSOME ABERRATION;
CHROMOSOME ANALYSIS;
CHROMOSOME LOSS;
CYTOMEGALOVIRUS INFECTION;
GENE SWITCHING;
HUMAN;
IMMUNOPHENOTYPING;
LEUKEMIA REMISSION;
MALE;
PHENOTYPE;
PRIORITY JOURNAL;
PROLYMPHOCYTIC LEUKEMIA;
T CELL LEUKEMIA;
|
EID: 0035691895
PISSN: 10428194
EISSN: None
Source Type: Journal
DOI: 10.1080/10428190127515 Document Type: Article |
Times cited : (21)
|
References (10)
|